Deals In Depth: December 2012
Biogen and Isis teamed up in their third antisense deal. Baxter paid $4 billion for its partner, dialysis company Gambro. Biopharma financing was boosted by Amarin’s large debt offering and a couple $100 million-plus FOPOs. Volcano’s $445 million notes deal drove device fundraising to $604 million.
You may also be interested in...
TransEnterix hires Shameze Rampertab as its new CFO and said it expects “modest growth” in Q3 and Q4.
Keeping Track: Viltepso Earns Priority Review Voucher; Manufacturing Trips Fennec; Eagle Drops Ryanodex Exertional Heat Stroke Bid
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
CureVac raised hundreds of millions of dollars this year before its $213m initial public offering as its mRNA vaccine technology moved into the COVID-19 spotlight. Its stock price tripled on its debut.